ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension

Chen, Shuang; Sun, Ping; Li, You; Shen, Wenqian; Wang, Chao; Zhao, Peng; Cui, Hao; Xue, Jing-Yi*; Du, Guo-Qing*广东省人民医院; 哈尔滨医科大学
European Journal of Pharmacology2022-10-15DOI: 10.1016/j.ejphar.2022.175262
7被引5阅读
引用收藏
分享

摘要

Among pulmonary arterial hypertension (PAH) patients, right ventricular (RV) functioning has been considered a major determining factor for cardiac capacity and survival. However, despite the recognition of the clinical importance for preserving RV functioning, no effective treatments are currently available for RV failure. This study aims to suggest one such possible treatment, through investigating the cardio-protective capabilities of the anti-oxidant, melatonin (Mel), for treating adverse RV remodeling in PAH, along with its underlying mecha-nisms. Arginine vasopressin induced neonatal rat cardiomyocyte hypertrophy in vitro; in vivo, PAH was induced in rats through intraperitoneal monocrotaline (MCT) injections, and Mel was administered intraperitoneally 24 h prior to MCT. Mel reduced rat cardiomyocyte hypertrophy and mitochondrial oxidative stress in vitro by acti-vating the Mst1-Nrf2 pathway, which were all reversed upon siRNA knockdown of Mst1. Likewise, in vivo, Mel pre-treatment significantly ameliorated MCT-induced deterioration in cardiac function, RV hypertrophy, fibrosis and dilation. These beneficial effects were also associated with Mst1-Nrf2 pathway up regulation and its asso-ciated reduction in oxidative stress, as evidenced by the decrease in RV malondialdehyde content. Notably, results from Mel treatment were similar, or even superior, to those obtained from N-acetyl cysteine (NAC), which has already been-confirmed as an anti-oxidative treatment for PAH. By contrast, co-treatment with the Mst1 inhibitor XMU-MP-1 reversed all of those Mel-associated beneficial effects. Our findings thus identified Mel as a potent cardio-protective agent against the onset of maladaptive RV remodeling, through enhancement of the anti-oxidative response via Mst1-Nrf2 pathway activation.

学科与关键词

关键词
MelatoninMst1Nrf2Pulmonary arterial hypertensionCardiac hypertrophyOxidative stress
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Pharmacology
发表日期
2022-10-15
卷期
第 933 卷
页码
175262
DOI
10.1016/j.ejphar.2022.175262
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; Guangdong Natural Sci-ence Foundation; Supporting Scientific Research Fund for High Level Talent Introduction of Guangdong Pro-vincial People?s Hospital; [82071948]; [2022A1515011675]; [KJ012021098]

作者

  • C

    Chen, Shuang (第一作者)

    2 · harbin med univ

  • S

    Sun, Ping

    2 · harbin med univ

查看全部 9 位作者收起作者
  • L

    Li, You

    2 · harbin med univ

  • S

    Shen, Wenqian

    2 · harbin med univ

  • W

    Wang, Chao

    2 · harbin med univ

  • Z

    Zhao, Peng

    2 · harbin med univ

  • C

    Cui, Hao

    2 · harbin med univ

  • X

    Xue, Jing-Yi (通讯)

    guangdong prov peoples hosp

  • D

    Du, Guo-Qing (通讯)

    guangdong prov peoples hosp · 2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417